重症虚血肢治療の世界市場2022-2031：産業分析、規模、シェア、成長、動向、予測

• 英文タイトル：Critical Limb Ischemia Treatment Market (Treatment: Medications [Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, and Others], and Devices: Embolic Protection Devices and Peripheral Dilatation System) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

• レポートコード：MRC2211A004 • 出版社/出版日：Transparency Market Research / 2022年8月 • レポート形態：英文、PDF、211ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥857,660 (USD5,795)	▷ お問い合わせ
Multi User	￥1,301,660 (USD8,795)	▷ お問い合わせ
Corporate License	￥1,745,660 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界の重症虚血肢治療市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場見通し、治療別（機器、薬物療法）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を掲載しています。なお、当書には、Medtronic plc、Boston Scientific Corporation、Cesca Therapeutics, Inc.、Abbott Laboratories、Pluristem Therapeutics, Inc.、Rexgenero Ltd.、LimFlow SA、Micro Medical Solutions、Cardiovascular Systems, Inc.などの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・市場見通し ・世界の重症虚血肢治療市場規模：治療別 - 機器の市場規模 - 薬物療法の市場規模 ・世界の重症虚血肢治療市場規模：地域別 - 北米の重症虚血肢治療市場規模 - ヨーロッパの重症虚血肢治療市場規模 - アジア太平洋の重症虚血肢治療市場規模 - 中南米の重症虚血肢治療市場規模 - 中東・アフリカの重症虚血肢治療市場規模 ・競争状況

Critical Limb Ischemia Treatment Market – Scope of Report

TMR’s report on the global critical limb ischemia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global critical limb ischemia treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global critical limb ischemia treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the critical limb ischemia treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global critical limb ischemia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global critical limb ischemia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global critical limb ischemia treatment market.

The report delves into the competitive landscape of the global critical limb ischemia treatment market. Key players operating in the global critical limb ischemia treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global critical limb ischemia treatment market profiled in this report.

RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market critical limb ischemia treatment.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

レポート目次

---

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers and Restraints Snapshot Analysis
4.2.2. Drivers
4.2.3. Restraints
4.2.4. Opportunity
4.3. Global Critical Limb Ischemia Treatment Market Revenue Projection (US$ Mn), 2017–2027
4.4. Global Critical Limb Ischemia Treatment Market Outlook
5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Industry Events
5.3. Regulatory Scenario for Device
5.4. Prevalence of Critical Limb Ischemia Globally/Region
5.5. Major Research Institutes Involved
5.6. Technological Advancement
6. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment
6.1. Key Findings
6.2. Introduction
6.3. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
6.4. Global Critical Limb Ischemia Treatment Market Forecast, by Treatment
6.4.1. Devices
6.4.2. Medication
6.5. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment
7. Global Critical Limb Ischemia Treatment Market Analysis, by Region
7.1. Global Critical Limb Ischemia Treatment Market Scenario, by Country
7.2. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Region
7.3. Global Critical Limb Ischemia Treatment Market Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
8. North America Critical Limb Ischemia Treatment Market Analysis
8.1. Key Findings
8.2. North America Critical Limb Ischemia Treatment Market Overview
8.3. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country
8.4. North America Critical Limb Ischemia Treatment Market Forecast, by Country
8.4.1. U.S.
8.4.2. Canada
8.5. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
8.6. North America Critical Limb Ischemia Treatment Market Forecast, by Treatment
8.6.1. Devices
8.6.2. Medication
9. Europe Critical Limb Ischemia Treatment Market Analysis
9.1. Key Findings
9.2. Europe Critical Limb Ischemia Treatment Market Overview
9.3. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
9.4. Europe Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
9.4.1. Germany
9.4.2. France
9.4.3. U.K.
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
9.6. Europe Critical Limb Ischemia Treatment Market Forecast, by Treatment
9.6.1. Devices
9.6.2. Medication
10. Asia Pacific Critical Limb Ischemia Treatment Market Analysis
10.1. Key Findings
10.2. Asia Pacific Critical Limb Ischemia Treatment Market Overview
10.3. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.4. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
10.6. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Treatment
10.6.1. Devices
10.6.2. Medication
11. Latin America Critical Limb Ischemia Treatment Market Analysis
11.1. Key Findings
11.2. Latin America Critical Limb Ischemia Treatment Market Overview
11.3. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Latin America Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
11.6. Latin America Critical Limb Ischemia Treatment Market Forecast, by Treatment
11.6.1. Devices
11.6.2. Medication
12. Middle East & Africa Critical Limb Ischemia Treatment Market Analysis
12.1. Key Findings
12.2. Middle East & Africa Critical Limb Ischemia Treatment Market Overview
12.3. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
12.6. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Treatment
12.6.1. Devices
12.6.2. Medication
13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
13.2.1. Medtronic plc
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Product Portfolio
13.2.1.3. SWOT Analysis
13.2.1.4. Strategic Overview
13.2.2. Boston Scientific Corporation
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Product Portfolio
13.2.2.3. SWOT Analysis
13.2.2.4. Strategic Overview
13.2.3. Cesca Therapeutics, Inc.
13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.3.2. Product Portfolio
13.2.3.3. SWOT Analysis
13.2.3.4. Strategic Overview
13.2.4. Abbott Laboratories
13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.4.2. Product Portfolio
13.2.4.3. SWOT Analysis
13.2.4.4. Strategic Overview
13.2.5. Pluristem Therapeutics, Inc.
13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.5.2. Product Portfolio
13.2.5.3. SWOT Analysis
13.2.5.4. Strategic Overview
13.2.6. Rexgenero Ltd.
13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.6.2. Product Portfolio
13.2.6.3. SWOT Analysis
13.2.6.4. Strategic Overview
13.2.7. LimFlow SA
13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.7.2. Product Portfolio
13.2.7.3. SWOT Analysis
13.2.7.4. Strategic Overview
13.2.8. Micro Medical Solutions
13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.8.2. Product Portfolio
13.2.8.3. SWOT Analysis
13.2.8.4. Strategic Overview
13.2.9. Cardiovascular Systems, Inc.
13.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.9.2. Product Portfolio
13.2.9.3. SWOT Analysis
13.2.9.4. Strategic Overview

List of Tables

Table 01: Pipeline Analysis

Table 02: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031

Table 03: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031

Table 04: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031

Table 05: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031

Table 06: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Region, 2022–2031

Table 07: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country, 2022–2031

Table 08: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031

Table 09: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031

Table 10: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022–2031

Table 11: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031

Table 12: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022–2031

Table 13: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031

Table 14: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031

Table 15: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022–2031

Table 16: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031

Table 17: Asia Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022–2031

Table 18: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031

Table 19: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031

Table 20: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022–2031

Table 21: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031

Table 22: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022–2031

Table 23: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031

Table 24: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031

Table 25: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022–2031

Table 26: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031

Table 27: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022–2031

Table 28: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031

Table 29: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031

Table 30: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System,

Table 31: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031

Table 32: Medtronic plc, Business Overview

Table 33: Boston Scientific Corporation Product Offerings

Table 34: Cesca Therapeutics Inc., Products & Services Offered

Table 35: Abbott Laboratories, Business Overview

Table 36: Pluristem Therapeutics Inc., Products & Services Offered

Table 37: Rexgenero Ltd, Products & Services Offered

Table 38: LimFlow SA, Products & Services Offered

Table 39: Micro Medical Solutions, Products & Services Offered

Table 40: Cardiovascular Systems, Inc., Products & Services Offered

---